Health Condition 1: null- Active Ulcerative colitis disease
Conditions
Interventions
Intervention1: VSL#3: VSL# 3(450 billion CFU) will be orally administered daily for a period of 12 weeks
Intervention2: VSL#3: VSL#3 (3600 billion CFU) will be administered daily for a period of 12 w
Sponsors
Department of Biotechnology
Eligibility
Inclusion criteria
Inclusion criteria: Active disease at presentation
Exclusion criteria
Exclusion criteria: Patient should not be on antibiotic, NSAIDs or indigenous medicine Pregnant or lactating mother Any patient who received probiotic in the preceding 4 weeks Patient with life threatning cardiac, renal, pulmonary or cardiovascular disease Inability to obtain informed consent Severe disease requiring hospitalization /steroids /anti-cytokine therapy Patient taking antiplatelet drugs Patient with uncontrolled diabetes patient with gall stone disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response will be defined as reduction of atleast 3 points in the UCDAI from the baseline value at 12 weeks; reduction in the activity score of inflammationTimepoint: 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction in intestinal permeability Reduction in faecal and serum inflammatory markersTimepoint: 12 weeks | — |
Countries
India
Contacts
Public ContactBikash Medhi
PGIMER
Outcome results
None listed